Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Vanda Pharmaceuticals in a research report on Monday, December 23rd.

Vanda Pharmaceuticals Price Performance

VNDA opened at $4.81 on Friday. The firm has a market capitalization of $280.46 million, a PE ratio of -17.18 and a beta of 0.76. The business’s 50-day moving average is $4.86 and its two-hundred day moving average is $5.18. Vanda Pharmaceuticals has a 1 year low of $3.46 and a 1 year high of $6.75.

Insider Buying and Selling

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the sale, the director now owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. The trade was a 10.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. purchased a new position in Vanda Pharmaceuticals during the 2nd quarter worth approximately $39,000. ORG Wealth Partners LLC acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter worth $40,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 4,374 shares during the last quarter. XTX Topco Ltd acquired a new position in Vanda Pharmaceuticals during the second quarter valued at $75,000. Finally, Intech Investment Management LLC purchased a new stake in Vanda Pharmaceuticals in the third quarter valued at $84,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.